Systemic scleroderma

Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update

Retrieved on: 
星期一, 六月 5, 2023
EASL, Pitango, Therapy, NASH, Norwest Venture Partners, Adi, Journal of Accounting and Economics, Clinical trial, CMMB, General partnership, Physiology, MBA, Biomarker, Certified Public Accountant, Doctor of Philosophy, Economics, Health care efficiency measures, Congress, TEL, Data analysis, MD, Patient, Investment, Biophysics, Fattal, Fatty liver disease, CFO, Knowledge, Growth, PSC, Systemic scleroderma, BA, Autoimmunity, Inflammation, Management, Pharmaceutical industry, Finance, Tel Aviv University, Accounting

(Nasdaq: CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced changes to its executive leadership team and provided a corporate update.

Key Points: 
  • (Nasdaq: CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced changes to its executive leadership team and provided a corporate update.
  • "I am excited to resume my corporate leadership responsibilities and look forward to continued engagement with our key stakeholders," said Dr. Mor.
  • "This transition of executive leadership to the company's founding team will focus on maintaining business continuity and ensuring clinical plan execution," continued Dr. Mor.
  • Adi's exceptional corporate leadership skills are complemented by her extensive knowledge in autoimmune, inflammatory and fibrotic diseases and broad experience in developing monoclonal antibodies.

Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis

Retrieved on: 
星期五, 六月 2, 2023
CCL24, University, Therapy, Serum, European Alliance of Associations for Rheumatology, CMMB, ILD, Prognosis, Primary sclerosing cholangitis, Scleroderma, Doctor of Philosophy, TEL, Incidence, Congress, Patient, European, DSM-IV codes, Risk, Poster, R, EULAR, European Alliance, Systemic scleroderma, Disease, Pharmaceutical industry, Rheumatology

MILAN and TEL AVIV, Israel, June 2, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced a poster presentation at the 2023 European Congress of Rheumatology, hosted by the European Alliance of Association for Rheumatology (EULAR) and held in Milan, Italy May 31–June 3, 2023.

Key Points: 
  • The poster, "CCL24 serum concentration predicts both vascular and fibrotic complications in systemic sclerosis," was presented today by Professor Enrico De Lorenzis of the Leeds Institute of Rheumatic and Musculoskeletal Diseases at the University of Leeds in the UK.
  • The study was conducted by Professor De Lorenzis and his colleagues who enrolled systemic sclerosis (SSc) patients from an observational cohort and compared them with age- and gender-matched controls.
  • 1 - CCL24 serum concentration predicts both vascular and fibrotic complications in systemic sclerosis, Enrico De Lorenzis, Adi Mor, Rebecca Ross, Stefano Di Donato, Revital Aricha, Hilit Levi, Ilan Vaknin, Francesco Del Galdo
    A copy of the poster will be available at the R&D portion of Chemomab's website.
  • For more information on the EULAR Congress, visit https://congress.eular.org/

AnaMar Announces Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis

Retrieved on: 
星期二, 五月 23, 2023
Therapy, Disability, ILD, Organ dysfunction, Biomarker, Scleroderma, Interstitial lung disease, Lung, EMA, Fibrosis, Vital capacity, Patient, CGMP, FDA, Death, Systemic scleroderma, Skin, Disease, Pharmaceutical industry, Research

LUND, Sweden, May 23, 2023 (GLOBE NEWSWIRE) -- AnaMar, a clinical-stage biotech company developing a first-in-class, peripheral 5-HT2B receptor antagonist, AM1476, as a pan anti-fibrotic medicine, announces positive results from its Phase I study, and the completion of Phase II enabling pre-clinical studies for its initial orphan indication in systemic sclerosis (SSc) characterized by lung and skin fibrosis.

Key Points: 
  • Skin fibrosis is a leading feature of SSc associated with significant disability.
  • The degree of skin fibrosis provides insight about progression of the disease.
  • Active product ingredients are being made ready as cGMP materials for this Phase II trial.
  • The company is planning regulatory submissions, in 2023, to the FDA and EMA for Orphan Drug Designation for the rare disease SSc.

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

Retrieved on: 
星期三, 五月 24, 2023
CCL24, EASL, Therapy, NASH, Liver, CMMB, Inflammation, Scleroderma, European Congress of Radiology, Doctor of Philosophy, Fibrosis, TEL, Congress, Patient, European Association for the Study of the Liver, EULAR, PSC, Systemic scleroderma, Primary sclerosing cholangitis, Pharmaceutical industry, Rheumatology

TEL AVIV, Israel, May 24, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced upcoming CM-101 data presentations at major European scientific conferences in June 2023, including EULAR23, the European Congress of Rheumatology, and EASL 2023, the Annual Congress of the European Association for the Study of the Liver.

Key Points: 
  • TEL AVIV, Israel, May 24, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced upcoming CM-101 data presentations at major European scientific conferences in June 2023, including EULAR23, the European Congress of Rheumatology, and EASL 2023, the Annual Congress of the European Association for the Study of the Liver.
  • Further details of the presented data will be forthcoming.
  • "Our poster presentations at EULAR and EASL highlight the novelty and potential of our unique approach to fibro-inflammatory diseases," said Dale Pfost, PhD, CEO of Chemomab.
  • EULAR23 – European Congress of Rheumatology – Milan, Italy, May 31-June 3, 2023

aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update

Retrieved on: 
星期二, 五月 9, 2023
Sarcoidosis, University, Small RNA, ATyr Pharma, Concept, ATS, Granuloma, Connective tissue, Clinical trial, ILD, Research, Scleroderma, American Thoracic Society, International Conference on Nuclear Disarmament, Oslo, 2008, Patient, Investment, SAN, Fibrosis, Systemic scleroderma, Vasculitis, Safety, Conference, D.C, D, Pharmaceutical industry, Bank, Communications satellite, Medicine

Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected to initiate in the third quarter of 2023.

Key Points: 
  • Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected to initiate in the third quarter of 2023.
  • Ended the first quarter 2023 with $117.6 million in cash, cash equivalents and investments.
  • SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced first quarter 2023 results and provided a corporate update.
  • G&A Expenses: General and administrative expenses were $3.4 million for the first quarter 2023.

aTyr Pharma Announces First Major Review Article for Efzofitimod Published in the Journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases

Retrieved on: 
星期四, 三月 30, 2023
Sarcoidosis, NRP2, University, Inflammation, Small RNA, ATyr Pharma, Granuloma, Quality of life, ILD, Scleroderma, Patient, SAN, Systemic scleroderma, Vasculitis, Pharmaceutical industry, Medicine

SAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) --  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the publication of a review article, titled, “Efzofitimod: a novel anti-inflammatory agent for sarcoidosis,” in the peer-reviewed journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases.

Key Points: 
  • SAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) --  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the publication of a review article, titled, “Efzofitimod: a novel anti-inflammatory agent for sarcoidosis,” in the peer-reviewed journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases.
  • The publication is available on the journal’s website and at: https://doi.org/10.36141/svdld.v40i1.14396 .
  • The authors also review the preclinical and clinical data generated for efzofitimod that support its anti-inflammatory properties and the potential for it to be a novel therapeutic approach to immune-mediated fibrotic lung diseases such as pulmonary sarcoidosis.
  • “Oral corticosteroids remain the cornerstone of treatment for symptomatic sarcoidosis, but long-term treatment often comes with significant side effects and reduced quality of life.

aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

Retrieved on: 
星期四, 三月 9, 2023
Transforming growth factor beta, EST, Medicine, IND, ATyr Pharma, Kyorin, European Medicines Agency, Conference, Clinical trial, Sarcoidosis, ILD, DC, Diagnosis, Interest, Food and Drug Administration, Systemic scleroderma, SAN, Committee, D, EMA, Fibrosis, Patient, FDA, Research, PST, Investigational New Drug, European Patent Office, Disease, American Thoracic Society, Food, Small RNA, European Patent Convention, Patent, Civil service commission, ATS, European Commission, Exercise, Investment, DARS, Scleroderma, Tokyo International Conference on African Development, Safety, Pharmaceutical industry, LTBP1, EU

SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2022 results and provided a corporate update.

Key Points: 
  • SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2022 results and provided a corporate update.
  • This achievement triggered a $10.0 million milestone payment to aTyr in the fourth quarter.
  • Based on the Company’s current operational plans and existing cash, aTyr believes the Company’s cash runway will extend into 2026.
  • Links to a live audio webcast and replay may be accessed on the aTyr website Events page at: http://investors.atyrpharma.com/events-and-webcasts .

aTyr Pharma Announces Phase 2 Study of Efzofitimod in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Following FDA Clearance of IND Application

Retrieved on: 
星期三, 三月 1, 2023
Death, Neuropilin, Small RNA, Autoimmune disease, Safety, Skin, News, Quality of life, Scleroderma, Inflammation, Sarcoidosis, Cleveland Clinic, ATyr Pharma, Fibrosis, Fast Track, NRP2, Disease, Investigational New Drug, IND, Cell, Standard of care, FDA, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Toxicity, Trial of the century, Systemic scleroderma, SAN, Idiopathic pulmonary fibrosis, Cleveland, Pathology, U.S. FDA, Scar, Food, Lung, Pharmaceutical industry, Medical imaging, ILD

SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today provided additional details regarding its plans to initiate a Phase 2 study of its lead therapeutic candidate, efzofitimod, in patients with systemic sclerosis (SSc, also known as scleroderma)-associated interstitial lung disease (ILD) following the clearance of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) announced earlier this year.

Key Points: 
  • Efzofitimod has been granted U.S. FDA orphan drug designation for SSc and Fast Track designation for SSc-ILD.
  • Efzofitimod is a potential first-in-class immunomodulator that downregulates innate and adaptive immune responses in uncontrolled inflammatory disease states via selective modulation of neuropilin-2 (NRP2).
  • The company is currently investigating efzofitimod in patients with pulmonary sarcoidosis, a major form of ILD, in a global Phase 3 study called EFZO-FIT™.
  • Current treatment options may help to slow lung function decline but do not impact underlying disease or improve quality of life.

Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis

Retrieved on: 
星期二, 二月 21, 2023
NASH, Biomarker, TEL, NAFLD, Scleroderma, Physician, Systemic scleroderma, Blood, Therapy, University, Food and Drug Administration, Non-alcoholic fatty liver disease, Tissue, Lung, Patient, CMMB, Clinical trial, Skin, Rheumatology, Food, Primary sclerosing cholangitis, Investigational New Drug, Pathology, Liver disease, Physiology, CCL24, Fatty liver disease, Disease, FDA, Orphan drug, PSC, Principal, Medical research, Doctor of Philosophy, IND, MD, Pharmaceutical industry, COVID

TEL AVIV, Israel, Feb. 21, 2023 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced U.S. Food and Drug Administration (FDA) clearance of the company's Investigational New Drug (IND) Application to evaluate CM-101 in a Phase 2 trial in adults with systemic sclerosis (SSc).

Key Points: 
  • In preclinical studies, CM-101 reduced inflammatory and fibrotic injury to the lung, skin and vasculature—organ systems often affected in SSc patients.
  • CM-101 has been granted Orphan Drug designation by the FDA for SSc and for primary sclerosing cholangitis (PSC), a rare liver disease.
  • Matt Frankel, MD, Chief Medical Officer of Chemomab, said, "Achieving FDA clearance to initiate our Phase 2 systemic sclerosis trial is an important milestone for Chemomab.
  • I welcome the opportunity to help launch and coordinate this innovative clinical trial for patients with SSc in the U.S., Europe and Israel, scheduled to open later this year."

aTyr Pharma Announces Pricing of Public Offering of Common Stock

Retrieved on: 
星期四, 二月 9, 2023
3rd Floor, Telephone, Scleroderma, Food, RNA transfection, Attention, ATyr Pharma, IND, Security (finance), RBC Capital Markets, Systemic scleroderma, S-3, Sale, Patient, SAN, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Equity capital markets, Form, Investigational New Drug, Park Avenue, Prospectus, Vesey Street

SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the pricing of its previously announced underwritten public offering of 22,225,000 shares of its common stock at a public offering price of $2.25 per share.

Key Points: 
  • SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the pricing of its previously announced underwritten public offering of 22,225,000 shares of its common stock at a public offering price of $2.25 per share.
  • The gross proceeds to aTyr from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $50.0 million.
  • In addition, aTyr has granted the underwriters a 30-day option to purchase up to an additional 3,333,750 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.
  • All of the shares being sold in the offering are being sold by aTyr.